{
    "title": "106_hr1039",
    "content": "CREDIT FOR CLINICAL TESTING RESEARCH EXPENSES ATTRIBUTABLE TO QUALIFIED ACADEMIC INSTITUTIONS INCLUDING TEACHING HOSPITALS. Amendment to the Internal Revenue Code of 1986 to include a new section 41A for a credit for medical innovation expenses. The medical innovation credit is 20% of qualified medical innovation expenses exceeding the medical innovation base period amount. Qualified expenses are those paid to a qualified academic institution for clinical testing research activities. The term 'qualified medical innovation expenses' refers to amounts paid to a qualified academic institution for clinical testing research activities. The term 'clinical testing research activities' refers to human clinical testing conducted at a qualified academic institution in the development of a product before its approval under the Federal Food, Drug, and Cosmetic Act. The date of approval or licensing for a product under various sections of the Federal Food, Drug, and Cosmetic Act or the Public Health Service Act is crucial for determining the timeline of clinical testing research activities. The Public Health Service Act defines a product as any drug, biologic, or medical device. A qualified academic institution is an educational institution. The term 'product' refers to any drug, biologic, or medical device. A qualified academic institution includes educational institutions and teaching hospitals. A teaching hospital affiliated with a 501(c)(3) organization and an institution of higher education as described in section 3304(f). Medical research organizations described in section 501(c)(3) must be affiliated with an organization meeting certain requirements, including being owned by an organization meeting the same requirements or a teaching hospital meeting specific criteria. Medical research organizations described in section 501(c)(3) must be affiliated with an organization meeting specific requirements or a teaching hospital meeting certain criteria. A hospital designated as a cancer center by the National Cancer Institute is considered a charitable research hospital. Qualified medical innovation expenses do not include amounts funded by grants. The term 'qualified medical innovation expenses' excludes amounts funded by grants or contracts from another person or governmental entity. The 'medical innovation base period amount' refers to the average annual qualified medical innovation expenses paid. The term 'medical innovation base period amount' refers to the average annual qualified medical innovation expenses paid by the taxpayer in the 3-taxable year period before the first taxable year after December 31, 1998. No credit is allowed for clinical testing funded by foreign sources. The taxpayer must elect to apply this section for any taxable year, with limitations on foreign clinical testing and rules similar to section 41. The taxpayer must elect to apply this section for any taxable year, with limitations on foreign research activities conducted outside the United States. Rules similar to section 41 apply, and coordination with other research credits is required. The taxpayer must elect to apply this section for any taxable year. Any qualified medical innovation expense for a taxable year under this section shall not be considered for the research credits under section 41 or 45C. This section does not apply to expenses incurred after the specified date in section 41(h)(1)(B). The innovation expense for a taxable year under this section is not considered for the research credits under section 41 or 45C. This section does not apply to expenses incurred after the specified date in section 41(h)(1)(B). The medical innovation expenses credit is added to the general business credit under Section 38(b) of the Code. No carryback of the Section 41A credit is allowed before enactment. The medical innovation expenses credit under Section 41A cannot be carried back to a taxable year before January 1, 1999 to prevent a double benefit. The medical innovation credit cannot be carried back to a year before 1999 to avoid a double benefit. No deduction is allowed for the portion of qualified medical innovation expenses equal to the credit amount. The new subsection (d) prohibits a deduction for the portion of qualified medical innovation expenses equal to the credit amount. This credit cannot be carried back before 1999 to prevent a double benefit. The new subsection (d) disallows a deduction for the portion of medical innovation expenses equal to the credit amount determined under section 41A(a). The tax code is amended to redefine qualified business credits and add a new paragraph for the medical innovation expenses credit. A clerical amendment is made to the table of sections. Sec. 41A introduces a credit for medical innovation expenses, effective for taxable years starting after December 31, 1998."
}